303 related articles for article (PubMed ID: 33968037)
1. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
Front Immunol; 2021; 12():645770. PubMed ID: 33968037
[TBL] [Abstract][Full Text] [Related]
2. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ.
Newey A; Yu L; Barber LJ; Choudhary JS; Bassani-Sternberg M; Gerlinger M
Cancer Res Commun; 2023 Nov; 3(11):2345-2357. PubMed ID: 37991387
[TBL] [Abstract][Full Text] [Related]
4. Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression.
Javitt A; Barnea E; Kramer MP; Wolf-Levy H; Levin Y; Admon A; Merbl Y
Front Immunol; 2019; 10():141. PubMed ID: 30833945
[TBL] [Abstract][Full Text] [Related]
5. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
6. New light on the HLA-DR immunopeptidomic landscape.
Egholm Bruun Jensen E; Reynisson B; Barra C; Nielsen M
J Leukoc Biol; 2024 Apr; 115(5):913-925. PubMed ID: 38214568
[TBL] [Abstract][Full Text] [Related]
7. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
Front Immunol; 2021; 12():662443. PubMed ID: 33936100
[TBL] [Abstract][Full Text] [Related]
8. Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens.
Ternette N; Olde Nordkamp MJM; Müller J; Anderson AP; Nicastri A; Hill AVS; Kessler BM; Li D
Proteomics; 2018 Jun; 18(12):e1700465. PubMed ID: 29786170
[TBL] [Abstract][Full Text] [Related]
9. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
Front Immunol; 2020; 11():1981. PubMed ID: 32983136
[TBL] [Abstract][Full Text] [Related]
10. Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging.
Han KC; Park D; Ju S; Lee YE; Heo SH; Kim YA; Lee JE; Lee Y; Park KH; Park SH; Lee HJ; Lee C; Jang M
Sci Rep; 2020 Apr; 10(1):5885. PubMed ID: 32245999
[TBL] [Abstract][Full Text] [Related]
11. ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
Oh CY; Klatt MG; Bourne C; Dao T; Dacek MM; Brea EJ; Mun SS; Chang AY; Korontsvit T; Scheinberg DA
Cancer Immunol Res; 2019 Dec; 7(12):1984-1997. PubMed ID: 31540894
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
13. Immunopeptidogenomics: Harnessing RNA-Seq to Illuminate the Dark Immunopeptidome.
Scull KE; Pandey K; Ramarathinam SH; Purcell AW
Mol Cell Proteomics; 2021; 20():100143. PubMed ID: 34509645
[TBL] [Abstract][Full Text] [Related]
14. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report.
Aran A; Peg V; Rabanal RM; Bernadó C; Zamora E; Molina E; Arribas YA; Arribas J; Pérez J; Roura-Mir C; Carrascal M; Cortés J; Martí M
Front Immunol; 2021; 12():761798. PubMed ID: 34868006
[TBL] [Abstract][Full Text] [Related]
16. The impact of immunopeptidomics: From basic research to clinical implementation.
Shapiro IE; Bassani-Sternberg M
Semin Immunol; 2023 Mar; 66():101727. PubMed ID: 36764021
[TBL] [Abstract][Full Text] [Related]
17. Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
Faridi P; Woods K; Ostrouska S; Deceneux C; Aranha R; Duscharla D; Wong SQ; Chen W; Ramarathinam SH; Lim Kam Sian TCC; Croft NP; Li C; Ayala R; Cebon JS; Purcell AW; Schittenhelm RB; Behren A
Cancer Immunol Res; 2020 Oct; 8(10):1322-1334. PubMed ID: 32938616
[TBL] [Abstract][Full Text] [Related]
18. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.
Kovalcsik E; John J; Turner M; Birchall L; Sage D; Whittle R; Dalgleish A; Pandha H
Melanoma Res; 2004 Dec; 14(6):463-71. PubMed ID: 15577316
[TBL] [Abstract][Full Text] [Related]
20. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
